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Abstract: Recent advances into the understanding of molecular mechanism of chronic pain have been largely developed 
through the use of genetic manipulations. This is in part due to the scarcity of selective pharmacological tools, which can 
be readily solved by creating knockout or transgenic mice. By identifying new genes that are of import, our efforts can 
then be aimed at studying relevant signaling pathways, and combination of pharmacological manipulations with genetic 
models can be used to further examine the specific mechanisms involved in chronic pain. In this review, we will examine 
the genetic models that are currently in use to study chronic pain in the anterior cingulate cortex: knockout mice; trans-
genic mice; and the strength of combining pharmacology with these genetic models. 
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INTRODUCTION 
  Pain is an essential sensory mechanism that warns us of immi-
nent tissue damage. However, clinical problems associated with 
pain occur when pain thresholds are dramatically altered. Pain is 
divided into two major categories: Acute or physiological pain and 
chronic or pathological pain [1,2]. Unlike physiological pain, which 
helps us to determine potentially dangerous stimuli and avoid it, 
making it essential for survival, pathological pain has no benefit 
and only occurs after insult (e.g., tissue or nerve injury or disease) 
[3,4]. In addition to spontaneous occurrences of pain, there are two 
common pathological conditions that develop after tissue or nerve 
injury: Allodynia, where the pain threshold has been reduced, al-
lowing non-noxious stimuli that normally do not cause pain to in-
duce pain, and hyperalgesia, in which there is an enhanced response 
to noxious stimuli [2].  
  Recent studies using animal models as well as human brain 
imaging techniques have consistently revealed that chronic pain is 
likely due to sensitization along the somatosensory pathways, in-
cluding long-lasting changes at peripheral tissue, spinal cord, and 
cortex [2]. Furthermore, descending biphasic modulatory systems 
that control the amount of pain information reaching the brain also 
undergo plastic changes [5]. Still, much about the molecular mecha-
nisms of chronic pain remain to be explored. Integrative 
experimental approaches including electrophysiological, pharma-
cological, biochemical, anatomical, and behavioral methods have 
proven to be useful for investigating the molecular mechanisms of 
chronic pain. In this review, we will focus on the use of genetically 
manipulated mice in studying synaptic and molecular mechanisms 
of chronic pain in the anterior cingulate cortex (ACC), an area 
known to mediate the emotional component of pain. We believe 
that the use of genetically manipulated mice offers not only com-
plete inhibition of the activity of target proteins than traditional 
pharmacological inhibitors, but better selectivity as well. Further-
more, the findings from genetic studies will help in the develop-
ment of novel and effective therapeutic agents to combat chronic 
pain.  
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MOUSE MODELS FOR INVESTIGATING CHRONIC PAIN 
  The mechanism of nociception is usually studied in rodents as 
the various stimuli used mimic clinical pain in humans. Addition-
ally, mice and humans share approximately 99% of their genes [6], 
which allows mice to be used as models of human physiology. A 
wide variety of chronic pain assays have been developed for the 
mouse, each examining different pain modalities. Inflammatory 
pain, which results from tissue damage and is reversible when the 
underlying cause has been rectified, is most commonly studied 
using the formalin test and injections of complete Freund’s adjuvant 
(CFA). The formalin test, a common test of tissue injury and in-
flammation on a timescale of hours, is used to model “acute” in-
flammation. Formalin is injected into the dorsum of the hindpaw, 
then spontaneous responses to the injection are measured [7,8]. 
Formalin-induced behavioral responses are typically categorized 
into two distinct phases: Phase one (0-10 min) and phase two (10-
55 min) [8], although we have previously shown that mice continue 
to exhibit behavioral responses during the 55-120 min period, a 
“phase three” [9]. Formalin-induced behavioral responses also de-
pend on NMDA receptors at different levels of the brain [10]. CFA, 
on the other hand, is a water-in-oil emulsion that contains heat 
killed Mycobacterium tuberculosis cell wall components. Much like 
formalin, CFA is injected into the dorsum of the hindpaw, although 
its effects can last for days. Following CFA injection, allodynia is 
typically observed on day 1 and 3 after injection by applying von 
Frey filament to the dorsum of the hindpaw to measure the with-
drawal responses.  
  Neuropathic pain results from damage to components of the 
nervous system, such as primary afferent nerves, spinal cord, and 
cortical regions [11]. As the onset of neuropathic pain may be de-
layed after a nerve injury, pain may still be present even after heal-
ing is complete [4,11]. Moreover, neuropathic pain commonly oc-
curs as a secondary symptom in diseases like diabetes and cancer, 
and may also occur with treatments, such as chemotherapeutics or 
cytotoxic drugs [11]. Furthermore, due to the dynamic nature of the 
pain system, the signs and symptoms of neuropathic pain change 
over time, and injury to peripheral nerve causes functional and bio-
chemical change to not only at the site of injury, but also to other 
parts of affected nerve and eventually to higher order neurons in the 
spinal cord and brain [4]. A number of animal models have been 
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The peripheral nerve injury models have been the most extensively 
studied, with the exact methods differing in the location and form 
of injury, including transaction and ligation [12]. Partial injury to 
the sciatic nerve is most commonly used to induce neuropathic pain 
behavior, including loose ligation of the sciatic nerve, developed by 
Bennett and Xie [13], as well as spinal L5/L6 nerve ligation, devel-
oped by Kim and Chung [14]. Recently, we have discovered a 
novel mouse model of neuropathic pain, a simple and less invasive 
procedure where the common peroneal nerve is ligated, leaving 
motor function intact [15]. The presence of neuropathic pain is 
mainly assessed by hyperalgesia to thermal and mechanical stimuli 
and allodynia to cold and tactile stimuli [12,14,16-18].  
  In addition to inflammatory pain and neuropathic pain, a wide 
variety of other pain assays have been developed to assess physio-
logical and pathological pain in mice, such as thermal nociception 
and visceral pain. List of the most used models have been provided 
below (see Table 1). 
Table 1.  Tests for Studying Physiological and Pathological Pain 
Physiological (Acute) Pain  Pathological (Chronic) Pain 
Thermal nociception  Inflammatory pain model 
Hot plate test  CFA 
Tail flick test  Formalin test 
Tail immersion test  Carrageenan 
Thermal test (Hargreaves’ test)   
Cold plate test  Neuropathic pain model 
  Chronic constriction injury of sciatic nerve 
Mechanical nociception  Partial sciatic nerve ligation 
Tail pinch  Spinal nerve ligation 
Paw pressure test  Common peroneal nerve ligation 
  Spared nerve injury model 
Visceral nociception  Infraorbital nerve ligation 
Colorectal distension  Loose ligation of sciatic nerve 
Writhing test   
  Diabetic model 
 Streptozotocin  injection 
 Alloxan  injection 
  
  Chemotherapeutic agent-induced model 
 Paclitaxel 
 Vincristine 
 Suramin 
 Cisplatin 
 Oxaliplatin 
 Carboplatin 
  
  Muscle pain model 
 Carrageenan 
 Capsaicin 
 Acidic  saline 
 
DELETION OF SIGNALING GENES 
  The availability of genetic mouse models has revolutionized 
biomedical research, and alterations to classical gene modification 
techniques have made possible the generation of conditional, induc-
ible, and multi-gene knockout mouse mutants. These techniques 
deliver a more detailed and informative look into the in vivo func-
tions and endogenous expression patterns of individual genes.  
  The basic premise behind the development of a knockout 
mouse is to replace the normal functioning gene with one that is 
nonfunctional (i.e., a null mutation) using homologous recombina-
tion. By comparing the phenotypes of these knockout mice to those 
of wild-type mice, the function of the targeted gene could then be 
deduced. If phenotypic differences exist between the knockout mice 
and their wild-type counterparts, it strongly suggests that the gene is 
responsible for or regulates that particular function. However, 
knockout technology has its limitations. Many knockout mice are 
embryonically lethal due to developmental defects, and some genes 
may serve a different function in adults than in developing embryos 
[19]. In such cases, conditional and inducible gene knockout tech-
nology can be used. Unlike the conventional knockout technology 
where the gene of interest is completely absent from all cells, con-
ditional knockouts by contrast inactivate the gene of interest in a 
tissue-specific manner, allowing greater control over gene expres-
sion. An inducible knockout enables the researcher to activate or 
inactivate the gene of interest at specific developmental time points, 
using antibiotic-controlled transcriptional activation, so that gene 
expression can be reversibly induced in the presence or absence of 
antibiotics, such as tetracycline [19].  
  There are several different ways to make conditional knockout 
models, but the most widely used is the Cre-loxP recombinase sys-
tem, where the target gene is modified through Cre action [20]. Cre 
expression can also be controlled temporally, by introducing an 
element into the promoter that requires a ligand, such as a drug, for 
induction [21].  
REGIONAL INHIBITION OF PROTEIN FUNCTIONS 
siRNA 
  In the past few years, RNA interference (RNAi) has revolution-
ized studies to determine the role of a gene and has become the 
predominant means of assessing loss of gene function in most or-
ganisms [22]. RNAi provides a rapid and easy means of depleting 
mRNAs by interfering with the expression of a specific gene [22]. 
Small interfering RNA (siRNA), sometimes known as short inter-
fering RNA or silencing RNA, is generally 20-25 basepairs long, 
and can be artificially introduced into cells by various transfection 
methods to bring about the specific knockdown of a gene of interest 
[23]. Any gene with a known sequence can be targeted based on 
sequence complementarity with an appropriately tailored siRNA, 
making it an important tool for gene function studies.  
  The efficacy of siRNA depends on multiple factors, including 
GC content and the thermodynamic stability of the duplex at the 5’ 
antisense end [24]. Several types of vectors for siRNA delivery 
have been developed to not only protect siRNAs from degradation 
but also for site-specific delivery and to enhance its cellular uptake. 
While non-viral vectors have the advantages of low toxicity, ease of 
synthesis and low immune response [25], viral vectors have the 
advantage of delivering siRNAs to neurons as well as glial cells, 
making it the most commonly used carriers for gene transfer. How-
ever, targeting specific cell types still remain a challenge. The ad-
vantage of efficient, economical knockdown offered by RNAi and 
the large amount of data provided makes it the current technology 
of choice, although overcoming the delivery obstacle for in vivo 
studies remains.  
Electroporation 
  Much like RNAi, the ability to transfer any gene of interest to a 
specific brain region has been a much sought-after technique. Sev-
eral approaches have been used to target gene transfer to neurons in 
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liposomal-plasmid complexes [29,30]. Electroporation, a technique 
where brief electrical pulses are applied to tissue to temporarily 
increase cellular permeability to DNA, has been used to enhance 
gene delivery into cells of adult organs, as well as neurons in the 
brains of embryonic mice [31]. Electroporation enables selective 
delivery of a gene to specific regions of the central nervous system 
(CNS), but unlike the transgenic approach, electroporation provides 
a method for unilateral gene transfer, allowing overexpression of a 
gene within a highly specific brain region [31]. Additionally, elec-
troporation provides a way to express a gene at any time during the 
development of normal or pathophysiological processes, allowing 
for investigations of the role of signaling proteins in numerous 
brain functions, and provides a method to rescue behavioral defects 
observed in genetically altered mice with fewer toxic effects when 
compared to other methods of gene transfer [31]. We have previ-
ously developed a microelectroporation method and selectively 
expressed both green fluorescent protein (GFP) and mutant 
calmodulin (CaM) in the ACC of adult rodents, the first instance 
where electroporation was used to deliver genes into the adult 
mammalian brain [31]. And recently, we have successfully com-
bined siRNA and electroporation to reduce the level of NR2B ex-
pression in the ACC of mice [32].  
GENETIC MANIPULATIONS IN INVESTIGATING 
CHRONIC PAIN IN THE ACC 
  Elucidating the function of particular neurotransmitters and 
their receptors has traditionally relied upon pharmacological ap-
proaches using compounds that act as specific agonists or antago-
nists at defined receptors on the pre- and postsynaptic membrane 
[33]. Unfortunately, selective antagonists of ion channels are lim-
ited, and lesion studies and local chemical injection experiments to 
dissociate behavioral responses to acute noxious stimuli from long-
term sensitization to the injury have failed, as these manipulations 
alone significantly affect behavioral responses to acute stimuli [7]. 
Therefore, researchers have turned to knockout and transgenic mice 
to investigate pain pathways.  
The Use of AC1 and AC8 Gene Knockout Mice 
  cAMP-related signaling pathway has previously been shown to 
contribute to the behavioral responses to tissue injury and inflam-
mation in the periphery and the spinal cord [34-37], but few studies 
have addressed the potential roles of forebrain cAMP in such 
changes. AC1 and AC8, two CaM-stimulated adenylyl cyclases 
(AC) in the CNS, couple NMDA receptor-induced cytosolic Ca
2+ 
increases to cAMP signaling pathways [38,39]. To examine the 
roles of AC1 and AC8 in behavioral sensitization within the ACC, 
an area mediating the emotional component of pain, we used AC1 
and AC8 knockout mice as well as AC1&8 double knockout 
(DKO) mice to determine the roles of these ACs in chronic pain [7] 
(Fig. 1). Behavioral nociceptive responses to subcutaneous formalin 
injection or nerve injury were significantly reduced in mice lacking 
AC1 or AC8, and more profoundly compromised in AC1&8 DKO 
mice. Allodynia was significantly reduced in AC1 KO mice and 
absent in AC1&8 DKO mice, but not in AC8 KO mice, indicating 
that ablation of AC8 alone is not sufficient to affect allodynia. We 
found that AC1 and AC8 were both expressed at high levels in two 
pain-related forebrain areas, the ACC and the insular cortex. Next, 
in order to determine whether the lack of allodynia was due to an 
acute requirement for AC1 and AC8 or the developmental changes 
in cortical function that occurred due to chronic deficiency of these 
isoforms, we attempted an acute behavioral rescue. Forskolin, a 
nonselective AC activator, was microinjected into the ACC of mice 
1 day following CFA injection to activate ACs, and we found that 
AC1&8 DKO mice were hypersensitive to the non-noxious stimu-
lus. Therefore, AC1 and AC8 are important for behavioral nocicep-
tive responses to nerve injury and inflammation, and the results 
suggest that AC1 and AC8 play important roles in the processing of 
nociceptive information in the ACC.  
Chemically-Engineered CaMKII Transgenic Mice 
  Ca
2+/CaM-dependent kinase II (CaMKII) is known to be a key 
molecule involved in regulating tissue-injury evoked persistent pain 
[40]. To determine the role of forebrain CaMKII in the develop-
ment of persistent pain, we used CaMKII F89G transgenic mice to 
spatially and temporally restrict the expression of CaMKII to the 
forebrain areas [41,42]. These mice were developed using the con-
ditional protein knockout/manipulation technique to achieve mono-
specific inhibition of a single kinase in one region of the mouse 
brain [41]. This method combined high temporal resolution of 
chemical inhibition with molecular and spatial specificity of genetic 
techniques [41]. We found that overexpressing CaMKII in the fore-
brain caused selective changes in synaptic LTD without causing 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Identifying a plasticity-selective gene for treating chronic pain. 
Inflammatory or nerve injuries cause both presynaptic and postsynaptic 
changes in the ACC synapses. Activity triggers the release of excitatory 
neurotransmitter glutamate, and activation of NMDAR leads to an increase 
in postsynaptic Ca
2+. Ca
2+ binds to CaM and leads to activation of calcium-
stimulated AC1 and Ca
2+/CaM-dependent protein kinases, resulting in pos-
sible postsynaptic trafficking of AMPA GluR1 receptors as well as increas-
ing AMPAR sensitivity to glutamate. Enhanced release of glutamate as well 
as postsynaptic changes in AMPAR-mediated responses contributes to 
enhanced noxious sensory information within the brain, and may be a pos-
sible cellular mechanism for chronic pain. Investigation of Molecular Mechanism of Chronic Pain  Current Genomics, 2010, Vol. 11, No. 1    73 
any obvious anatomical abnormality or changes in neuronal excit-
ability. Additionally, enhanced CaMKII activity in the forebrain 
resulted in significant reduction in mechanical allodynia 1 and 3 
days after CFA injection into the dorsum of a single hindpaw, as 
well as reduction in thermal hyperalgesia. CaMKII mice were then 
treated with the inhibitor 1NM-PP1 to turn off the overexpressed 
CaMKII activity. We found that the inhibitor treatment completely 
blocked the effects of CaMKII overexpression on behavioral allo-
dynia and hyperalgesia in transgenic mice, and synaptic transmis-
sion was rescued as well. The results suggest that the enhanced 
forebrain CaMKII activity reduced behavioral sensitization to pe-
ripheral injury, and that the loss of LTD in CaMKII transgenic mice 
may be responsible for the reduction of nociceptive responses after 
tissue injury (Fig. 2A).  
Octopamine Mice 
  To investigate the synaptic mechanisms related to inflammatory 
pain, we used transgenic mice with heterologously expressed recep-
tors impacting the cAMP pathway [43]. The mice heterologously 
expressed an Aplysia octopamine receptor (Ap oa1) [44], a G pro-
tein-coupled receptor selectively activating the cAMP pathway after 
the binding of its natural ligand, octopamine [45]. There were at 
least two advantages in using these transgenic mice: First, as Ap oa1 
receptor expression is driven by CaMKII promoter, the receptor is 
selectively expressed in forebrain neurons, allowing the cAMP 
pathway coupled to Ap oa1 receptor to be spatially activated; and 
second, that since the receptor is not activated endogenously, the 
exogenous application of octopamine is the only way of activating 
Ap oa1 receptor and the associated cAMP pathway. 
  Octopamine is a trace amine and its endogenous level is far 
below those of classical neurotransmitters. Therefore, we selec-
tively activated cAMP pathway by microinjecting octopamine into 
the ACC then tested behavioral responses to the formalin test [43]. 
We found enhancement in the intermediate inflammatory phase but 
not in the acute phase, indicating that the enhancement is selective 
for late phase responses. And activation of Ap oa1 receptors in the 
ACC enhanced presynaptic glutamate release but didn’t modulate 
postsynaptic function, suggesting that these heterologous receptors 
are expressed in presynaptic terminals modulating vesicle release, 
and that increased presynaptic glutamate release in the ACC is suf-
ficient for enhancing chronic pain (Fig. 2B). 
Forebrain NR2B Overexpressed Mice 
  Functional NMDA receptors contain heteromeric combinations 
of the NR1 subunit plus one or more of NR2A-D [46], of which the 
NR2A and NR2B subunits are the major NR2 subtypes found in 
forebrain structures [47]. Using transgenic mice with forebrain-
targeted overexpression of the NMDA receptor subunit NR2B, we 
examined their response to tissue injury and inflammation [8]. We 
found that transgenic mice exhibited prominent NR2B expression 
and enhanced NMDA receptor-mediated synaptic responses in two 
pain-related forebrain areas, the ACC and insular cortex. Addition-
ally, these mice exhibited enhanced responsiveness to peripheral 
injection of two inflammatory stimuli: Formalin, where the en-
hancement was observed in the last phase, and CFA, where at day 1 
and 3 after CFA injection, mechanical allodynia was significantly 
enhanced in the transgenic mice. We then showed that the NR2B 
receptor undergoes prolonged upregulation in the ACC neurons 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Two examples of combining chemical and genetic approaches. 
A. Inflammatory pain triggers the release of excitatory neurotransmitter glutamate, and activation of NMDAR leads to an increase in postsynaptic Ca
2+. Ca
2+ 
binds to CaM and leads to activation of Ca
2+/CaM-dependent protein kinases such as CaMKII. Overexpression of CaMKII leads to reduction in LTD as well 
as allodynia and hyperalgesia, suggesting that the observed reduction in behavioral sensitization may be due to the loss of LTD. 
B. Activation of presynaptic Ap oa1 by octopamine leads to the production of cAMP. The cAMP-related signaling pathways then facilitate the release of glu-
tamate, which in turn acts on NMDAR and AMPAR. This triggers the downstream signaling pathways, leading to increased behavioral sensitization. 74    Current Genomics, 2010, Vol. 11, No. 1  Kim et al. 
after tissue inflammation, with enhanced NMDA receptor-mediated 
responses [48]. Inhibition of NR2B receptors by administering se-
lective NR2B receptor antagonists (Ro 25-6981 and Ro 63-1908) 
systematically as well as by bilateral microinjection into the ACC 
inhibited inflammation-related allodynia, suggesting that this in-
crease contributes to chronic pain by enhancing the neuronal activ-
ity of the ACC (Fig. 3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Identifying a cognitive gene in chronic pain. 
Peripheral injury such as tissue inflammation or nerve injury leads to a burst 
of abnormal activity, and subsequently activates postsynaptic NMDAR. 
This triggers Ca
2+ influx, leading to activation of Ca
2+/CaM-dependent 
pathways, including AC1. AC1 activation leads to the generation of cAMP, 
which activates PKA. PKA then translocates to the nucleus and phosphory-
lates CREB. Postsynaptic synthesis of NMDA NR2B is then increased, and 
the new NR2B subunits are added to postsynaptic NMDAR. This may fur-
ther enhance neuronal excitability and contribute to chronic pain. 
 
CaMKIV Gene Knockout Mice 
  There has been some debate over whether increased behavioral 
responses seen in “smart” mice on chronic pain tests genuinely 
reflect the severity of pain rather than the mice being better learn-
ers. In order to address this concern, we conducted fear memory as 
well as pain tests on CaMKIV knockout mice. CaMKIV, like 
CaMKII, is a key Ca
2+/calmodulin-dependent kinase, and functions 
as a transcriptional activator [49-51]. We found that fear memory 
was significantly reduced in CaMKIV knockout mice, but behav-
ioral responses to an acute noxious stimulus or prolonged injury 
remained comparable to wild-type mice [52]. The results indicate 
that CaMKIV is preferentially involved in fear memory induced by 
a noxious shock but not in behavioral responses to acute noxious 
stimuli or tissue inflammation, and that the two can be disassociated 
at the molecular level (Fig. 4). Therefore, although many signaling 
pathways may contribute to normal physiological functions as well 
as to distorted pathological conditions, it is possible to identify 
signaling molecules that preferentially contribute to one but not the 
other. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). CaMKIV distinguishes fear memory and chronic pain. 
Inflammatory or nerve injuries trigger the release of excitatory neurotrans-
mitter glutamate, and activation of NMDAR leads to an increase in postsyn-
aptic Ca
2+. Ca
2+ binds to CaM and leads to activation of Ca
2+/CaM-
dependent protein kinases, such as CaMKIV. In the absence of CaMKIV, 
fear memory was significantly reduced but behavioral responses to painful 
stimuli remained unchanged, indicating that fear memory and pain may be 
dissociated at the molecular level. 
 
SUMMARY AND FUTURE DIRECTIONS 
  Recent advances in genetic manipulations have transformed 
physiology and medicine by allowing for a direct investigation into 
the function of specific genes, significantly improving our knowl-
edge of the pain pathway. Previous studies have indicated that in 
the ACC, Ca
2+-stimulated cAMP pathways are necessary for 
chronic pain behaviours, and that selective elevation of cAMP is 
sufficient to enhance chronic pain. As well, NMDA receptors and Investigation of Molecular Mechanism of Chronic Pain  Current Genomics, 2010, Vol. 11, No. 1    75 
their related signaling pathways in the forebrain have been impli-
cated in injury-related behavioral sensitization [8,31,53]. Consis-
tently, behavioral sensitization after tissue injury appears to be 
regulated or modulated by neuronal activity within the forebrain 
areas. The knockout and transgenic mice provide a powerful tool 
for investigating the roles of genes and proteins in chronic pain, but 
further work remains to be done. More selective signaling proteins 
that are involved in chronic pain still remain to be discovered. 
Combination of different techniques is clearly needed to elucidate 
the exact cellular mechanisms of chronic pain. 
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